The 13 most recent market catalysts affecting $EYPT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 75
TD Cowen Downgrades EyePoint to Hold, Lowers Price Target to $4
TD Cowen analyst Tara Bancroft downgraded EyePoint Pharmaceuticals (EYPT) from a 'Buy' rating to a 'Hold' rating. Concurrently, the price target for EYPT was drastically reduced fr…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 75
EyePoint shares are trading higher after a Form 4 filing indicated that a company Director bought 10,600 shares at an average price of $4.93 per share.
This headline signifies a positive corporate catalyst for EyePoint Pharmaceuticals. Insider buying, especially by a Director, is generally viewed favorably by the market as it sugg…
Aug 18, 2026
Corporate Catalyst
Bearish
Impact 95
These Analysts Slash Their Forecasts On EyePoint
EyePoint announced that its DURAVYU Phase 3 LUGANO trial for wet AMD failed to meet its primary visual acuity endpoint, attributing it to a 'confounding patient subgroup.' While th…
Aug 18, 2026
Corporate Catalyst
Bearish
Impact 75
RBC Capital Downgrades EyePoint to Sector Perform, Lowers Price Target to $5
RBC Capital's downgrade of EyePoint Pharmaceuticals (EYPT) from Outperform to Sector Perform, coupled with a dramatic price target reduction from $37 to $5, signals a significant s…
Aug 18, 2026
Corporate Catalyst
Bearish
Impact 75
Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5
Chardan Capital's downgrade of EyePoint Pharmaceuticals from 'Buy' to 'Neutral' and the dramatic reduction of its price target from $65 to $5 is a significant event for the company…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 55
JP Morgan Downgrades EyePoint to Neutral
JP Morgan analyst Tessa Romero downgraded EyePoint (EYPT) from Overweight to Neutral. This is a direct change in investment recommendation from a prominent financial institution, s…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 75
Jefferies Maintains Buy on EyePoint, Lowers Price Target to $8
Jefferies analyst Kambiz Yazdi maintained a 'Buy' rating on EyePoint (EYPT) but drastically cut the price target from $30 to $8. This move signals a significant downward revision i…
Aug 17, 2026
Corporate Catalyst
Bearish
Impact 95
EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study
EyePoint Inc. (EYPT) released topline data from its pivotal Phase 3 LUGANO trial for DURAVYU, a wet AMD treatment. The trial failed to meet its primary visual acuity endpoint, lead…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 85
EyePoint Announces Topline Results From LUGANO, First Pivotal Phase 3 Clinical Trial For DURAVYU For Treatment Of Wet Age-Related Macular Degeneration
EyePoint announced topline results from its LUGANO Phase 3 trial for DURAVYU in wet AMD. While the primary endpoint of change from baseline in best corrected visual acuity (BCVA) w…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Cantor Fitzgerald Maintains Overweight on EyePoint, Raises Price Target to $55
Cantor Fitzgerald analyst Steve Seedhouse maintained an 'Overweight' rating on EyePoint Pharmaceuticals and raised the price target from $47 to $55. This action signals increased c…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 92
EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K Estimate
EyePoint Pharmaceuticals announced its Q2 earnings, revealing a loss of $(1.09) per share, which was worse than the analyst consensus of $(0.95). This EPS miss, coupled with a 28.2…
Jul 16, 2026
Corporate Catalyst
Neutral
Impact 75
Stifel Initiates Coverage On EyePoint with Buy Rating, Announces Price Target of $40
Stifel analyst Annabel Samimy has initiated coverage on EyePoint Pharmaceuticals (EYPT) with a 'Buy' rating and a $40 price target. This is a significant event for EYPT as new anal…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.